As our Clinical Director of SABR and MRI-guided radiotherapy, Dr James Good is a national leader in innovative cancer treatment.
James is a Consultant Clinical Oncologist with a focus on cutting edge, personalised treatment of cancers of the head & neck, bowel and rectum using chemotherapy, radiotherapy, targeted therapy, and immunotherapy. He also specialises in advanced radiotherapy techniques for liver and pancreatic tumours, secondary tumours in lung, bone and lymph node, and retreatment of cancer previously targeted with radiotherapy. James’ patients tell him they value his warm, honest and pragmatic approach. He strives to combine an emphasis on clear and compassionate communication with a drive to get the best possible outcome from cancer treatment for everyone under his care.
James has shaped GenesisCare’s role as the leading independent provider of stereotactic ablative radiotherapy (SABR/SBRT). Through a short course of highly targeted therapy, SABR can change the outlook for people with advanced and inoperable tumours – having treated over 250 patients, James is among the most experienced SABR specialists in the UK. He is also a pioneer in MRI-guided radiotherapy, a technology available at our Oxford centre that makes possible a new level of precision in the treatment of liver, pancreas and other cancers with SABR.
After training as a scientist at Cambridge University, James trained in medicine at University College, London. Following further clinical training in London and Oxford he spent six years at the Royal Marsden and Guy’s Hospitals developing expertise in cancer medicine. James now divides his time between his work in Birmingham and Oxford, and family life in Worcestershire.
Secretary: Sheena Colline
Tel: 0121 371 3599
Private clinic information
- Monday, 09:00 – 18:00: GenesisCare Oxford (for MRI-linac referrals)
- Tuesday, 18:00 – 19:00: BMI Priory Hospital, Edgbaston
- Friday, 17:00-19:00: Spire Little Aston Hospital/GenesisCare, Sutton Coldfield
- Committee member, UK SABR Consortium
- Appointed member, NCRI clinical and translational radiotherapy group (CT-Rad)
- Fellow, Royal College of Radiologists
- Member, Royal College of Physicians
- Member, Radiosurgery Society
- Member, European Society of Medical Oncology
Dr Good is the local lead clinician on several clinical trials investigating both immunotherapy and novel radiation techniques. He has a particular interest in novel drug/radiotherapy combinations. He is also on the trial management group of the phase 3 CompARE trial, investigating immunotherapy in combination with radiotherapy, and is deputy chief investigator of the WISTERIA trial, which investigates a DNA damage response modulator with radiotherapy. He is involved in shaping the national research strategy for patients with primary liver cancer and has published a wide range of research work.